GCIA
CDTX

Gabelli & Co Investment Advisers’s Cidara Therapeutics CDTX Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-95,805
Closed -$21.2M – 305
2025
Q4 		$21.2M Buy
+95,805
New +$15.5M 3.18% 7

Gabelli & Co Investment Advisers's CDTX Position: Q1 2026 in Review

Gabelli & Co Investment Advisers sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 95,805 shares — an estimated $21.2M sold.

Gabelli & Co Investment Advisers first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $21.2M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

  • Gabelli & Co Investment Advisers reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 95,805 Cidara Therapeutics shares in Q1 2026, an estimated $21.2M.
  • Gabelli & Co Investment Advisers first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Cidara Therapeutics position peaked at $21.2M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.